DEF: Adicet Bio Sets Date for 2025 Annual Meeting, Outlines Key Proposals

Adicet Bio announces its 2025 Annual Meeting of Stockholders to be held virtually on June 11, 2025, featuring director elections, executive compensation advisory vote, and auditor ratification.

Summary

• Adicet Bio, Inc. will hold its 2025 Annual Meeting of Stockholders online on June 11, 2025, at 5:00 p.m. Eastern Time.
• Stockholders of record as of April 15, 2025, are entitled to vote.
• The meeting will include the election of two class I directors, an advisory vote on executive compensation, and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The board of directors has nominated Katie Peng and Chen Schor for election as class I directors.
• Dr. Jakobovits has not been nominated to stand for re-election when her current term expires at the Annual Meeting.
• The company is providing access to proxy materials over the Internet, mailing a Notice of Internet Availability of Proxy Materials on or about April 29, 2025.
• Stockholders can vote online, by phone, or by mail, with specific deadlines for each method.
• The board recommends voting for the election of Katie Peng and Chen Schor, for the approval of executive compensation, and for the ratification of KPMG LLP's appointment.
• KPMG LLP served as the company's independent registered public accounting firm since 2020.
• The audit fees paid to KPMG LLP were $592,800 for fiscal year 2024 and $796,500 for fiscal year 2023.

Sentiment

Score: 7

Explanation: The document is neutral in tone, presenting standard corporate governance matters. The sentiment is slightly positive due to the routine nature of the announcements and adherence to regulatory requirements.

Positives

• The company is utilizing the SEC's Notice and Access rules to reduce costs and environmental impact.
• Stockholders have multiple options for voting, including online, phone, and mail.
• The Audit Committee pre-approves all audit and non-audit services provided by the independent registered public accounting firm.
• The company has a compensation recovery policy in place.

Negatives

• Dr. Galimi resigned from his position as chief medical officer, effective December 13, 2024.
• Dr. Jakobovits has not been nominated to stand for re-election when her current term expires at the Annual Meeting.
• Immediately prior to the opening of the polls at the Annual Meeting, our Board has elected to reduce the size of our Board from eight to seven directors.

Risks

• Failure to reach a quorum could result in adjournment of the Annual Meeting.
• Advisory vote on executive compensation is non-binding, so the board may not fully implement stockholder feedback.
• The payments and benefits provided to Mr. Harvey in connection with a change in control may not be eligible for a federal income tax deduction for the company pursuant to Section 280G of the Internal Revenue Code of 1986, as amended, or the Code, and may subject Mr. Harvey to an excise tax under Section 4999 of the Code.

Future Outlook

The company plans to announce preliminary voting results at the Annual Meeting and will publish final results in a Current Report on Form 8-K to be filed with the SEC within four business days following the Annual Meeting.

Industry Context

This announcement is a standard part of corporate governance, ensuring shareholders have the opportunity to participate in key decisions regarding the company's direction and oversight.

Comparison to Industry Standards

• The virtual format of the annual meeting aligns with current trends in corporate governance, offering accessibility to a broader range of shareholders.
• The company's approach to executive compensation and director independence is consistent with Nasdaq listing requirements and SEC regulations.
• The disclosure of audit fees and the pre-approval policy for audit services are standard practices for publicly traded companies.

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction through voting on key proposals.
• Employees are indirectly affected by the advisory vote on executive compensation.
• The selection of an independent auditor impacts the credibility of the company's financial reporting.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold the Annual Meeting on June 11, 2025, and announce the results shortly thereafter.
• The board of directors will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Executive Compensation, KPMG, Audit Committee, Stockholders, Voting, Adicet Bio